1. Checkpoint inhibitor‐induced bullous pemphigoid differs from spontaneous bullous pemphigoid.
- Author
-
Kramer, N., Müller, G., Zierold, S., Röckel, M., Fröhlich, W., Schefzyk, M., Kumbrink, J., Hassel, J. C., Berking, C., Ziemer, M., Nashan, D., French, L. E., Vera, J., Kerl‐French, K. E., Gutzmer, R., and Heinzerling, L.
- Subjects
- *
BULLOUS pemphigoid , *JAK-STAT pathway , *DRUG side effects - Abstract
This article discusses the differences between checkpoint inhibitor-induced bullous pemphigoid (irBP) and spontaneous bullous pemphigoid (BP). The study compared patients with irBP to patients with BP and found that irBP patients were younger, had a shorter duration of disease, and had a better therapeutic response. However, irBP patients required permanent discontinuation of ICI therapy in 78% of cases. The article provides clinical characteristics and treatment information for both irBP and BP patients. The study also identified differentially expressed genes in irBP compared to BP and normal skin tissue, suggesting potential targets for irBP treatment. The JAK-STAT signaling pathway was found to be enriched in both irBP and BP, indicating that JAK inhibitors could be potential treatment options. The study was funded by grants and the authors declare potential conflicts of interest. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF